Although anti-VEGF antibodies yield significant additive effects in conditions where VEGF is a key factor, such as metastasis to the central nervous system [49, 50], malignant pleural effusion [51], and pericardial effusion, its use still requires caution. The gene discussed is VEGFA; the disease is pericardial effusion.